Open AccessComparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea
Author(s) -
Parveen Jain,
Vidya Nand Rabi Das,
Alok Ranjan,
Rahul Chaudhary,
Krishna Pandey
Publication year - 2013
Publication title -
journal of research in pharmacy practice
Language(s) - English
Resource type - Journals
eISSN - 2319-9644
pISSN - 2279-042X
DOI - 10.4103/2279-042x.128145
Subject(s) - medicine , imatinib , myeloid leukemia , white blood cell , quality of life (healthcare) , repeated measures design , leukemia , analysis of variance , adverse effect , oncology , gastroenterology , statistics , nursing , mathematics
Chronic myeloid leukemia (CML) is a clonal hematopoietic disorder caused by acquired genetic defect in pluripotent stem cells characterized by acquisition of the philadelphia chromosome. The aim of this study was to compare the efficacy, safety and quality of life (QoL) in CML patients treated with imatinib or hydroxyurea.